Management of no-reflow: Still an unsolved problem?
2 University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Received: 18-Feb-2020 Accepted Date: Mar 05, 2020; Published: 12-Mar-2020
Citation: Mirizzi AM, Spolverini M, Attanasio A, Crimi G. Management of noreflow Still an unsolved problem? J Phlebol Lymphol 2020;13(1):1-7.
This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact [email protected]
No-reflow represents an important limitation of percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Importantly, no-reflow is associated with an increased risk of major adverse cardiac events. In this review, we discuss the pharmacological and nonpharmacological interventions proposed for the prevention and treatment of no-reflow, highlighting the new updates and evidences on efficacy of these approaches.